Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
未接受過胰島素治療的2型糖尿病患者中,Efsitora與Degludec的比較。
N Engl J Med 2024-09-10
Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
直接比較固定比例組合的胰高血糖素受體激動劑和基礎胰島素對第2型糖尿病的血糖和非血糖參數的影響。
BMC Endocr Disord 2023-02-06
Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip.
Empagliflozin和Semaglutide(每週一次)在Shtip地區T2DM患者中的療效和安全性。
Pril (Makedon Akad Nauk Umet Odd Med Nauki) 2023-10-09
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
一周一次 efpeglenatide 在血糖控制不佳的 2 型糖尿病患者中的療效和安全性:AMPLITUDE-D、AMPLITUDE-L 和 AMPLITUDE-S 隨機對照試驗。
Diabetes Obes Metab 2023-07-04
Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial.
一周一次的dulaglutide在二型糖尿病患者中的葡萄糖代謝控制:從DPP4抑制劑轉換,與每日empagliflozin附加治療比較,這些患者在二甲双胍、磺脲类药物和DPP4抑制劑治療下控制不佳:一項隨機試驗。
Diabetes Res Clin Pract 2023-10-08
Effectiveness of insulin degludec/liraglutide versus insulin degludec/insulin aspart in Japanese patients with type 2 diabetes.
日本患者中胰島素 degludec/liraglutide 與胰島素 degludec/胰島素 aspart 治療二型糖尿病的效果。
Diabetol Int 2024-03-26
Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
週期性 Tirzepatide 與週期性胰島素在第二型糖尿病中的比較療效和安全性:隨機臨床試驗的網絡 Meta 分析。
Diabetes Obes Metab 2024-06-26
Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial.
Visepegenatide在2型糖尿病單獨治療中的療效和安全性:一項隨機、雙盲、平行、安慰劑對照的3期試驗。
Lancet Reg Health West Pac 2024-07-01
Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
Tirzepatide 在管理 2 型糖尿病方面優於長效胰島素:三項第三期隨機對照試驗的 meta-analysis。
Int J Obes (Lond) 2024-08-29
Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients.
早期將強化胰島素療法轉換為IDegLira在降低2型糖尿病患者的空腹血糖和HbA1c方面顯示出更高的療效和安全性。
Diabetes Metab Syndr Obes 2024-09-03